Compare HCA Health Inc (HCA) vs LyondellBasell Industries NV (LYB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HCA Health Inc vs LyondellBasell Industries NV — how do they compare? HCA Health Inc trades at $450.18 (market cap $96.35B), while LyondellBasell Industries NV trades at $60.13 (market cap $19.49B). The key difference: HCA Health Inc is far larger — about 4.9× LyondellBasell Industries NV's market cap, and LyondellBasell Industries NV pays the higher dividend (4.57%). Which is the better fit depends on your goals — on Pluang, investors hold HCA Health Inc for 76 Days and LyondellBasell Industries NV for 87 Days on average.
| HCA | LYB | |
|---|---|---|
Market Cap | $96.35B | $19.49B |
Volume | 1,079,453 | 6,033,396 |
Sector | Health | Basic Materials |
52-Week High | $545.13 | $82.38 |
52-Week Low | $361.32 | $42.28 |
Typical Hold Time | 76 Days | 87 Days |
Enterprise Value | $146.88B | $31.08B |
Dividend Yield | 0.7% | 4.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare trades at $449.47, up 2.35% with bullish technical indicators and strong fundamental performance. The stock shows consistent earnings beats with Q2 2026 EPS of $7.59 exceeding expectations, while revenue growth continues from $75.6B in 2025 to projected $78.0B in 2026. Analyst consensus remains strongly positive with 63% buy ratings and $461.12 price target, though legal investigations present headwinds.
The outlook remains favorable with solid patient demand and operational efficiency driving growth, though investors should monitor ongoing legal investigations and debt levels. Valuation appears reasonable with P/E of 14.92 and EV/EBITDA of 9.26, while technical support at $440 provides near-term stability.
LYB trades at $60.90, up 4.12% today, with a bearish technical signal and mixed fundamentals. Revenue declined to $30.15B in 2025, with a net loss of $745M, though recent quarters show earnings beats. The stock is near its 52-week low, with key support at $60. Analyst consensus is split evenly between Buy and Hold, with a $69.38 price target. Recent news highlights dividend sustainability concerns amid chemical sector volatility.
Outlook remains cautious due to profitability challenges and high debt, but operational improvements and a 45% analyst buy rating suggest recovery potential. Risks include cyclical demand, margin pressure, and dividend coverage issues. The stock offers value at current levels if earnings stabilize, but investors should monitor cash flow trends and sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →
